Clearmind Medicine Inc. announced a significant achievement as the first participant has been dosed with its proprietary oral drug candidate, CMND-100, in a Phase I/IIa clinical trial aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results